In the prophylactic setting, pairing JAK2 inhibition with established strategies like post-transplant cyclophosphamide (PTCy) or abatacept may enable steroid-sparing regimens that maintain graft-versus-leukemia (GvL) activity [33]. This evidence concerns the gene JAK2 and leukemia.